Anlon Healthcare, a manufacturer of pharmaceutical intermediates, has submitted initial paperwork to the Securities and Exchange Board of India or SEBI for an initial public offering (IPO). This IPO is expected to raise significant funds, with the entire offering consisting of a fresh issue of 1.4 crore equity shares, as detailed in the draft papers filed on October 9. Notably, there will be no offer-for-sale component included in this IPO.
Fund allocation for growth
The company plans to allocate the proceeds from the IPO strategically. Here’s how they intend to invest in IPO proceeds:
Company overview and ownership structure
Anlon Healthcare operates from Gujarat, where it has one manufacturing facility and four research and development (R&D) labs. Punitkumar Rasadia and Meet Atulkumar Vachhani co-found the company. The promoters maintain a significant 70.26% ownership stake, while the public holds the remaining 29.74%.
Anlon Healthcare focuses on producing advanced pharmaceutical intermediates, which are essential raw materials for active pharmaceutical ingredients (APIs). These APIs play a critical role in the production of various pharmaceutical formulations, including tablets, capsules, ointments, and syrups. They are also integral in the nutraceuticals sector, as well as in personal care and animal health products.
Unique market position
The company stands out as one of the few manufacturers of loxoprofen sodium dihydrate, an API frequently prescribed for conditions like rheumatoid arthritis, osteoarthritis, and post-surgical pain.
Anlon Healthcare boasts a diverse product portfolio, featuring 65 commercialised products, 28 in the pilot stage and 49 in various stages of R&D.
Interactive Financial Services is the sole merchant banker for the IPO, while KFin Technologies acts as the registrar.
Key takeaways
Investing in IPOs like Anlon Healthcare could be a strategic opportunity for those looking to enter the pharmaceutical sector.
For android only